Choice of antihypertensive drugs in the European Society of Hypertension–European Society of Cardiology guidelines: specific indications rather than ranking for general usage-Reference-Cited by-同舟云学术

Choice of antihypertensive drugs in the European Society of Hypertension–European Society of Cardiology guidelines: specific indications rather than ranking for general usage

Published:2008-02 Issue:2 Volume:26 Page:164-168
ISSN:0263-6352
Container-title:Journal of Hypertension
language:en
Short-container-title:

Author:

Mancia Giuseppe,Zanchetti Alberto

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Reference41 articles.

1. Task force for the management of arterial hypertension of the European Society of Hypertension–European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension;Mancia;J Hypertens,2007

2. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomized controlled trial;Dahlöf;Lancet,2005

3. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol;Dahlöf;Lancet,2002

4. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH).;J Hypertens,1985

5. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial;Wilhelmsen;J Hypertens,1987

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines;Hypertension;2024-05

2. Valorización de lías de vino como ingredientes antihipertensivos;BIO Web of Conferences;2023

3. Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified;Blood Pressure;2022-08-26

4. Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines;Hypertension;2022-06

5. Role of Chrononutrition in the Antihypertensive Effects of Natural Bioactive Compounds;Nutrients;2022-05-04